These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 35579429)
21. Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients. Rizzello F; Viciani E; Gionchetti P; Filippone E; Imbesi V; Melotti L; Dussias NK; Salice M; Santacroce B; Padella A; Velichevskaya A; Marcante A; Castagnetti A Front Cell Infect Microbiol; 2024; 14():1352202. PubMed ID: 38510960 [TBL] [Abstract][Full Text] [Related]
22. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Zuo T; Liu Q; Zhang F; Yeoh YK; Wan Y; Zhan H; Lui GCY; Chen Z; Li AYL; Cheung CP; Chen N; Lv W; Ng RWY; Tso EYK; Fung KSC; Chan V; Ling L; Joynt G; Hui DSC; Chan FKL; Chan PKS; Ng SC Microbiome; 2021 Apr; 9(1):91. PubMed ID: 33853691 [TBL] [Abstract][Full Text] [Related]
23. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. Zhang F; Wan Y; Zuo T; Yeoh YK; Liu Q; Zhang L; Zhan H; Lu W; Xu W; Lui GCY; Li AYL; Cheung CP; Wong CK; Chan PKS; Chan FKL; Ng SC Gastroenterology; 2022 Feb; 162(2):548-561.e4. PubMed ID: 34687739 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome. Rosas-Salazar C; Kimura KS; Shilts MH; Strickland BA; Freeman MH; Wessinger BC; Gupta V; Brown HM; Rajagopala SV; Turner JH; Das SR J Allergy Clin Immunol; 2021 Apr; 147(4):1226-1233.e2. PubMed ID: 33577896 [TBL] [Abstract][Full Text] [Related]
25. The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity. Kim JG; Zhang A; Rauseo AM; Goss CW; Mudd PA; O'Halloran JA; Wang L J Med Virol; 2023 Feb; 95(2):e28445. PubMed ID: 36583481 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of co-circulating pathogens and microbiome from COVID-19 infections. Thissen JB; Morrison MD; Mulakken N; Nelson WC; Daum C; Messenger S; Wadford DA; Jaing C PLoS One; 2022; 17(12):e0278543. PubMed ID: 36455065 [TBL] [Abstract][Full Text] [Related]
28. Exoproducts of the Most Common Sahl C; Baumgarten M; Shannon O; Påhlman LI Microbiol Spectr; 2023 Aug; 11(4):e0019523. PubMed ID: 37284754 [No Abstract] [Full Text] [Related]
29. SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts. Hoque MN; Sarkar MMH; Rahman MS; Akter S; Banu TA; Goswami B; Jahan I; Hossain MS; Shamsuzzaman AKM; Nafisa T; Molla MMA; Yeasmin M; Ghosh AK; Osman E; Alam SKS; Uzzaman MS; Habib MA; Mahmud ASM; Crandall KA; Islam T; Khan MS Sci Rep; 2021 Dec; 11(1):24042. PubMed ID: 34911967 [TBL] [Abstract][Full Text] [Related]
30. Induction of interferon response by high viral loads at early stage infection may protect against severe outcomes in COVID-19 patients. Rouchka EC; Chariker JH; Alejandro B; Adcock RS; Singhal R; Ramirez J; Palmer KE; Lasnik AB; Carrico R; Arnold FW; Furmanek S; Zhang M; Wolf LA; Waigel S; Zacharias W; Bordon J; Chung D Sci Rep; 2021 Aug; 11(1):15715. PubMed ID: 34344959 [TBL] [Abstract][Full Text] [Related]
31. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand. Pongchaikul P; Santanirand P; Antonyuk S; Winstanley C; Darby AC FEMS Microbiol Lett; 2020 Jul; 367(14):. PubMed ID: 32592387 [TBL] [Abstract][Full Text] [Related]
32. Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Nardelli C; Gentile I; Setaro M; Di Domenico C; Pinchera B; Buonomo AR; Zappulo E; Scotto R; Scaglione GL; Castaldo G; Capoluongo E Front Cell Infect Microbiol; 2021; 11():625581. PubMed ID: 33659220 [TBL] [Abstract][Full Text] [Related]
33. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment. Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850 [No Abstract] [Full Text] [Related]
34. Dysbiosis and structural disruption of the respiratory microbiota in COVID-19 patients with severe and fatal outcomes. Hernández-Terán A; Mejía-Nepomuceno F; Herrera MT; Barreto O; García E; Castillejos M; Boukadida C; Matias-Florentino M; Rincón-Rubio A; Avila-Rios S; Mújica-Sánchez M; Serna-Muñoz R; Becerril-Vargas E; Guadarrama-Pérez C; Ahumada-Topete VH; Rodríguez-Llamazares S; Martínez-Orozco JA; Salas-Hernández J; Pérez-Padilla R; Vázquez-Pérez JA Sci Rep; 2021 Oct; 11(1):21297. PubMed ID: 34716394 [TBL] [Abstract][Full Text] [Related]
35. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
36. NGS analysis of nasopharyngeal microbiota in SARS-CoV-2 positive patients during the first year of the pandemic in the Campania Region of Italy. Giugliano R; Sellitto A; Ferravante C; Rocco T; D'Agostino Y; Alexandrova E; Lamberti J; Palumbo D; Galdiero M; Vaccaro E; Pagliano P; Weisz A; Giurato G; Franci G; Rizzo F Microb Pathog; 2022 Apr; 165():105506. PubMed ID: 35358660 [TBL] [Abstract][Full Text] [Related]